ARKG241129C25500
- 0.13
- -0.22-62.86%
ARK Genomic Revolution ETF Newsroom
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages
Guardant Health Shares Are Trading Higher After a Jury Issued a Decision in the Company's Favor Regarding a False Advertising Case Filed by Natera Concerning Statements Made About Guardant's Reveal Test.
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
Twist Bioscience Shares Are Trading Higher After Leerink Partners Maintained Its Hold Rating on the Stock.
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Goldman's Hedge Fund VIP List: AMZN, VST, CRM, BABA, and More
Recursion Pharmaceuticals Analyst Ratings
Trump Media Saw the Largest Increase in Short Interest in October
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $48
Twist Bioscience Analyst Ratings
12 Health Care Stocks Moving In Monday's Pre-Market Session
Analyst Expectations For Natera's Future
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
Veracyte Analyst Ratings
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Top Wall Street Forecasters Revamp Twist Bioscience Price Expectations Ahead Of Q4 Earnings
Twist Bioscience Q4 2024 GAAP EPS $(0.59) Beats $(0.70) Estimate, Sales $84.71M Beat $82.20M Estimate
Earnings Scheduled For November 18, 2024